Company: OPGN
Filing Date: 2025-08-21
Form Type: 10-K
Source: 0001829126-25-006628
Chunk: 491

Company: OPGEN INC
Filing Date: 2025-08-21
Form: 10-K
Item: Item 1C
Chunk 491
---
 -

    25,926

    Short-term insurance financing

    90,278

    -

    Short-term notes payable

    -

    10,873,867

    Current portion of finance lease liabilities

    -

    280

    Current portion of operating lease liabilities

    173,726

    147,943

    Total current liabilities

    634,181

    11,422,242

    Operating lease liabilities, net of current portion

    1,847,889

    2,021,616

    Total liabilities

    2,482,070

    13,443,858

    Commitments and Contingencies (Note 10)

    Stockholders’ equity (deficit):

    Series D Preferred stock, $0.01 par value; 10,000,000 shares authorized; 250 shares issued and outstanding at December 31, 2024 and 2023

    2

    2,500

    Common stock, $0.01 par value; 100,000,000 shares authorized; 10,070,779 and 1,282,686 shares issued and outstanding at December 31, 2024 and 2023, respectively

    100,708

    12,827

    Additional paid-in capital

    300,780,440

    293,991,529

    Accumulated deficit

    (293,500,522
    )

    (305,493,302
    )
  
    Accumulated other comprehensive loss

    -

    (75,138
    )
  
    Total stockholders’ equity (deficit)

    7,380,628

    (11,561,584
    )
  
    Total liabilities and stockholders’ equity (deficit)
     
    $
    9,862,698

    $
    1,882,274

See accompanying notes to consolidated financial statements.

F-5

OpGen, Inc.

Consolidated Statements of Operations and
Comprehensive Income (Loss)

    Year Ended December 31,

    2024

    2023

    Revenue

    Product sales
     
    $
    169,373

    $
    2,400,053

    Laboratory services

    26,776

    153,719

    Listing sponsorship services

    5,000,000

    -

    Collaboration revenue